UA99747C2 - Crystalline chemotherapeutic - Google Patents

Crystalline chemotherapeutic

Info

Publication number
UA99747C2
UA99747C2 UAA201006034A UAA201006034A UA99747C2 UA 99747 C2 UA99747 C2 UA 99747C2 UA A201006034 A UAA201006034 A UA A201006034A UA A201006034 A UAA201006034 A UA A201006034A UA 99747 C2 UA99747 C2 UA 99747C2
Authority
UA
Ukraine
Prior art keywords
chemotherapeutic
crystalline
crystalline chemotherapeutic
indazol
methylphenyl
Prior art date
Application number
UAA201006034A
Other languages
English (en)
Ukrainian (uk)
Inventor
Томас Б. Борчардт
Original Assignee
Эбботт Леборетриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40174825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA99747(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эбботт Леборетриз filed Critical Эбботт Леборетриз
Publication of UA99747C2 publication Critical patent/UA99747C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Описаны кристаллическая форма 1 1/4 этанолата N-[4-(3-амино-1Н-индазол-4-ил)фенил]-N'-(2-фтор-5-метилфенил)мочевины, способы ее получения, композиции, которые ее содержат, и композиции, полученные с ее применением, а также способы лечения пациентов с ее применением.
UAA201006034A 2007-10-19 2008-10-16 Crystalline chemotherapeutic UA99747C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98131007P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
UA99747C2 true UA99747C2 (en) 2012-09-25

Family

ID=40174825

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201006034A UA99747C2 (en) 2007-10-19 2008-10-16 Crystalline chemotherapeutic

Country Status (25)

Country Link
US (1) US7994208B2 (ru)
EP (1) EP2195300B1 (ru)
JP (2) JP5878689B2 (ru)
KR (1) KR20100085986A (ru)
CN (1) CN101827821B (ru)
AR (1) AR068918A1 (ru)
AU (1) AU2008312528A1 (ru)
BR (1) BRPI0818067A2 (ru)
CA (1) CA2699302C (ru)
CL (1) CL2008003091A1 (ru)
CO (1) CO6280482A2 (ru)
CR (1) CR11387A (ru)
DO (1) DOP2010000113A (ru)
EC (1) ECSP10010182A (ru)
ES (1) ES2547878T3 (ru)
GT (1) GT201000093A (ru)
MX (1) MX2010004288A (ru)
PA (1) PA8800301A1 (ru)
PE (1) PE20091075A1 (ru)
RU (1) RU2010119927A (ru)
TW (1) TW200932728A (ru)
UA (1) UA99747C2 (ru)
UY (1) UY31408A1 (ru)
WO (1) WO2009052225A1 (ru)
ZA (1) ZA201002180B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994208B2 (en) * 2007-10-19 2011-08-09 Abbott Laboratories Crystalline chemotherapeutic
US20140212355A1 (en) * 2013-01-28 2014-07-31 Abbott Cardiovascular Systems Inc. Trans-arterial drug delivery
JP7346916B2 (ja) * 2019-06-04 2023-09-20 京セラドキュメントソリューションズ株式会社 緩衝構造体およびそれを備えた包装材

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
EP2246333B1 (en) 2003-05-22 2012-10-24 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
EP1925941B1 (en) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
US9006240B2 (en) * 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
CN101346128B (zh) 2005-10-25 2013-10-02 雅培制药有限公司 包含低水溶解度药物的配方及其使用方法
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
MX2009004861A (es) * 2006-11-09 2009-05-21 Abbott Gmbh & Co Kg Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.
US7994208B2 (en) * 2007-10-19 2011-08-09 Abbott Laboratories Crystalline chemotherapeutic

Also Published As

Publication number Publication date
JP5878689B2 (ja) 2016-03-08
MX2010004288A (es) 2010-04-30
JP2011500704A (ja) 2011-01-06
WO2009052225A1 (en) 2009-04-23
GT201000093A (es) 2012-03-12
CA2699302A1 (en) 2009-04-23
CA2699302C (en) 2016-06-21
AR068918A1 (es) 2009-12-16
US7994208B2 (en) 2011-08-09
EP2195300A1 (en) 2010-06-16
ES2547878T3 (es) 2015-10-09
TW200932728A (en) 2009-08-01
PE20091075A1 (es) 2009-08-27
ECSP10010182A (es) 2010-06-29
CN101827821B (zh) 2012-09-05
US20090105326A1 (en) 2009-04-23
KR20100085986A (ko) 2010-07-29
CL2008003091A1 (es) 2009-09-04
DOP2010000113A (es) 2010-07-31
PA8800301A1 (es) 2009-08-26
EP2195300B1 (en) 2015-06-24
ZA201002180B (en) 2011-10-26
AU2008312528A1 (en) 2009-04-23
BRPI0818067A2 (pt) 2015-03-31
CR11387A (es) 2010-08-18
RU2010119927A (ru) 2011-11-27
CN101827821A (zh) 2010-09-08
UY31408A1 (es) 2009-05-29
CO6280482A2 (es) 2011-05-20
JP2015042650A (ja) 2015-03-05

Similar Documents

Publication Publication Date Title
AR060150A1 (es) Heteropentaciclos activos como inhibidores de quinasas, y su uso para tratar trastornos de la proliferacion celular
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
UA99747C2 (en) Crystalline chemotherapeutic
UA99489C2 (en) Crystalline chemotherapeutic agent
MX2010004287A (es) Productos quimioterapeuticos cristalinos.
UA101961C2 (en) 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
UA99746C2 (ru) Кристаллическое химиотерапевтическое средство на основе индазола
MX2010003771A (es) Forma cristalina 2 - de 2 ((r)-2-metilpirrolidin-2-il)-1h-benzimid azol-4-carboxamida.
DOP2010000116A (es) Productos quimioterapeuticos cristalinos
CL2009000496A1 (es) Formas cristalina tipo iii de (3,5-bis trifluorometil)-n-[4-metil-3-(4-piridin-3-il)-pirimidin-2-ilamino)-fenil]-benzamida; proceso de preparacion de la forma cristalina iii; composion farmaceutica que compende la forma cristalina iii; y su uso como agente antitumoral.
DK1904511T3 (da) Homogemcitabin
TH104744A (th) สารทางเคมีบำบัดที่เป็นผลึก